Searched for
GLUMETZA
Lupin Q2 results: Firms posts Rs 2,095 crore loss due to one-off impairmentsDuring the quarter, the company booked a provision of Rs 1879.6 crore towards litigation and settlement related to diabetic drug Glumetza c...- Granules gets American drug regulator's nod for diabetes management drug MetforminThe US Food and Drug Administration (USFDA) has granted final approval for the company's abbreviated new drug application (ANDA) for Metfor...
- Buy Lupin, target price Rs 1,040: NomuraIn FY21F the company is also likely to incur one-time additional expenses of $10 million related to the recall of Metformin extended-releas...
- Glenmark Pharma gets USFDA nod for diabetes management drug"Glenmark Pharmaceuticals Inc, USA, has been granted final approval by the United States Food & Drug Administration (USFDA) for metformin h...
- Lupin's weak Q1 nos take toll: Brokerages cut target priceAnalysts expect the current financial year to be challenging for the company in terms of US sales.
- Credit Suisse cuts Lupin target price post Q1 resultLupin had registered a net profit of Rs 881.95 crore for the corresponding period of the previous fiscal.
- Lupin posts 59% drop in consolidated net profit at Rs 358 crore in Q1The pharma firm had reported Rs 881.95 crore profit in the corresponding quarter last year.
- Credit Suisse sees Lupin’s EPS hit as Fortamet, Glumetza losing volume sharePrescriptions for Fortamet and Glumetza market are down 13% QoQ (quarter on quarter), which could impact FY18 EPS for Lupin by 5%.
- Growth will come on the back Gavis consolidation: Ramesh Swaminathan, CFO, Lupin"This year Gavis will actually add tremendously to the growth. We also have other molecules to launch after Glumetza and Fortament gets pha...
- Lupin looks to launch 25 products in US this fiscalIn the current year, apart from the Gavis portfolio, Fortamet and Glumetza, the company expects to launch products like Minastrin and Epzic...
- Sun Pharma slips despite USFDA nod for generic diabetes drugAt 12:11 pm, shares of the pharma giant were trading at Rs 836.70 apiece, up 0.19 per cent from its previous close on Bombay Stock Exchange...
- With several firms getting USFDA clearances, Street to breathe easy about pharma stocksLast week, Lupin, Cadila Healthcare and Alembic Pharma received clearances from the US regulator for their key facilities.
- Buy Lupin with a target at Rs 1850: BofA-MLThe Q4 results were a strong beat on the back of healthy 20 per cent beat in EBITDA. Higher gross margins in Glumetza led margin growth des...
- Lupin nosedives 8% even as drugmaker reports 47% PAT growth in Q4The company had reported PAT of Rs 547 crore in the same quarter last financial year.
- Buy Lupin with a Target Rs 1850: BofA-MLThe Q4 results were a strong beat on the back of healthy 20 per cent beat in EBITDA. Higher gross margins in Glumetza led margin growth des...
- It may take another quarter for Lupin to post a robust showMumbaibased pharma company Lupin has posted better-than-expected numbers after reporting dismal figures for four successive quarters.
- Lupin launches generic diabetes drug in the USLupin has launched 10 products in the US this fiscal year and has received approvals for 21 from the FDA. The drug maker has 35 FTF product...
- Lupin gets USFDA nod for diabetes drugLupin has received US health regulator's approval to sell its generic version of Glumetza HCl ER Tablets in US market.
- Lupin settles patent dispute with US firms over diabetes drugLupin today said it has reached a patent litigation settlement agreement with US-based firms Santarus Inc and Depomed Inc involving diabete...
- Lupin gets USFDA approval for diabetes drugLupin today said it has received approval from the US health regulator for its Metformin Hydrochloride Extended Release tablets, used in tr...
Load More
